

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
19 November 2020 (19.11.2020)



(10) International Publication Number
WO 2020/229974 A1

(51) International Patent Classification:

C07D 413/06 (2006.01) *A61K 51/04* (2006.01)
C07D 413/14 (2006.01) *A61K 51/10* (2006.01)
A61K 31/4427 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/IB2020/054381

(22) International Filing Date:

08 May 2020 (08.05.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/846,044 10 May 2019 (10.05.2019) US

(71) Applicant: **JANSSEN BIOTECH, INC.** [US/US];
800/850 Ridgeview Drive, Horsham, Pennsylvania 19044
(US).

(72) Inventors: **SALTER, Rhys**; Welsh & McKean Rds.,
Spring House, Pennsylvania 19477 (US). **DUDKIN,**
Vadim; 1400 McKean Road, Spring House, Pennsylvan-
ia 19477 (US). **SONG, Fengbin**; 1400 McKean Road,
Spring House, Pennsylvania 19477 (US). **ZHANG, Wei**;
1400 McKean Road, Spring House, Pennsylvania 19477
(US). **GOLDBERG, Shalom**; 1400 McKean Road, Spring
House, Pennsylvania 19477 (US). **KEITH, John**; 3210
Merryfield Row, San Diego, California 92121 (US).

(74) Agent: **SHIRTZ, Joseph F.** et al.; Johnson & Johnson,
One Johnson & Johnson Plaza, New Brunswick, New Jer-
sey 08933 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: MACROCYCLIC CHELATORS AND METHODS OF USE THEREOF



(I)

(57) Abstract: Macrocyclic chelators (I) for chelation of alpha-emitting radiometal ions, such as actinium-225 are provided. Also provided are radiometal complexes containing an alpha-emitting radiometal ion bound to the macrocyclic chelator via coordinate bonding, and radioimmunoconjugates containing the radiometal complexes covalently linked to a targeting ligand, such as an antibody or antigen binding fragment thereof. The radioimmunoconjugates can be produced by click chemistry reactions. Methods of using the radiocomplexes and radioimmunoconjugates for selectively targeting neoplastic cells for radiotherapy and for treating neoplastic diseases and disorders are also described.

WO 2020/229974 A1